Review of ISPE's Baseline Guide for Oral Solid Dosage Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Review of ISPE's Baseline Guide for Oral Solid Dosage Forms
The author outlines the key concepts of ISPE's recently revised Baseline Pharmaceutical Guide for New and Renovated Facilities. This article is part of a special supplement on Excipients and Solid Dosage.


Pharmaceutical Technology
Issue 34, pp. s6-s12

Contamination risk. The level of protection is based on the risk of contamination as assessed by the manufacturer. Assessment criteria include:

  • Duration of product exposure
  • Product mix and product changeover (i.e., product changeover is the frequency of change of product processed in a room or in a piece of equipment)
  • Characteristics such as potency or toxicity
  • Human activities performed in the manufacturing process
  • Facility design and performance factors
  • Environment in which the plant is located.

Design conditions and operating range . Operating conditions are based upon product-acceptance criteria while design set points and conditions are target values for the engineering designer to achieve. For example, a blending room may have a setpoint of 40% relative humidity (RH) and a design range of 30–50% RH, but the product in that room may be unaffected by humidity in the range of 20–70% (i.e., validated product-acceptance criteria). The acceptable operating range for the room is therefore 20–70%, not 30–50%. Additionally, nonproduct requirements such as human comfort are also criteria in the design (4).

GEP. GEP is defined as engineering practices that are applied throughout the business to provide organization and control, balance risk and cost, and deliver appropriate and effective solutions. GEP describes an engineering-management system that is expected in a pharmaceutical enterprise but not mandated by good practice quality (i.e., GxP) regulations. GEP recognizes that all systems in a facility undergo some form of commissioning, which include inspection, testing, and documentation based on agreed protocols. Direct-impact systems require enhanced documentation, which includes an enhanced design review, and quality-assurance (QA) inspection and approval that are appropriate and acceptable to regulators. GEP capitalizes upon the suggestion that manufacturers engage all stakeholders (i.e., engineers, managers, operators, and QA experts) early in the planning, design, construction, commissioning, and qualification phases to ensure that systems are documented only once (5, 6).


Cost factors for an oral solid-dosage manufacturing facility
Documentation. Appropriate documentation throughout the project for ensuring the equipment and facility is fit for its intended use is a key element of GEP. Documentation should be reviewed, approved by appropriate subject matter experts, updated in a timely fashion, and stored in a secure location for retrieval (1).

Major elements of the OSD guide


Quality risk management
The OSD guide is subdivided into chapters that cover the following: regulatory philosophy; product protection, product, and processing; architectural and facility design; process support and utilities; heating, ventilation, and air-conditioning (HVAC) systems; electrical requirements; control and instrumentation; and other considerations. The appendixes provide insight into cost factors for OSD manufacturing (see sidebar, "Cost factors for an oral solid-dosage manufacturing facility") and outline the quality risk-management process and tools (see sidebar, "Quality risk management) (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here